article · Sohag Medical Journal
Background: Covid-19 infection is a highly infectious illness with high mortality especially among elderly patients with chronic illnesses . During the pandemic of Covid-19 , it is necessary to find a screening method to predict the patients at high risk for developing severe immortal disease . increased interleukin-6 (IL-6) is a key factor contributing to the cytokine storm syndrome involved in clinical manifestations of Covid-19. Aim of the work: to determine the significance of Interleukin- 6 as a predictive factor of Hypoxemia and the severity of Covid-19 infection . Subjects and Methods: Case - Control study was done at Abassia Fever hospital and Ain Shams University Isolation Hospitals on 75 persons (50 patients with different grades of severity for Covid-19 disease and 25 controls) during 6 months duration from September 2021 to March 2022 . Results: we found a statistically significant difference as regard serum IL-6 between critically severe , mild and control groups with more increased levels of IL-6 between died patients than survived patients . Conclusion: Neutrophil-Lymphocyte Ratio , CRP , ESR , Ferritin and Albumin were associated with increased disease severity and worse clinical outcome but IL-6 was found to be better than them in predicting disease severity . the level of IL-6 > 12.6 pg/mL at the initial presentation had excellent sensitivity and specificity in predicting the development of hypoxia demanding hospitalization . Further larger studies are needed to predict the significance of IL-6 as an effective screening method for the severe Covid-19 disease .
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/smj.2024.326114.1497
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.